Latest Breaking News On - மருத்துவ சோதனைகள் குழு - Page 5 : comparemela.com

 E-Mail Los Angeles, Calif. - The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, today announced the addition of two monoclonal antibodies, BMS-986414 and BMS-986413, to the COVID-19 outpatient treatment study, ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial. BMS-986414 and BMS-986413 will be administered as subcutaneous injections (shots) given at one visit. ACTIV-2 includes both phase 2 and phase 3 evaluations of multiple investigational agents for treating early COVID-19 in a single trial. For information about enrolling in the trial, please visit the study website. Given that prevention and treatment will continue to be an important part of ending the COVID-19 pandemic, it is key that we identify and develop a variety of treatment options, said ACTG Chair Judith Currier, M.D., M.Sc., University of California, Los Angeles (UCLA). ACTIV-2 is studying a number of different therapeutic approaches, including infusions, shots, pi

United statesSan diegoLos angelesDavey smithJosephj eronJudith currierKatya coradoBrii biosciencesErics daarDavid alain wohlCamostat sagent pharmaceuticalsUniversity of californiaNational institutes of healthNational institute of allergyClinical trials groupUniversity of north carolina